Bausch + Lomb Rolls Out enVista Envy Premium Intraocular Lens Across Europe
Easter Sale - 70% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Bausch + Lomb Corporation ( (BLCO) ) just unveiled an announcement.
Bausch + Lomb has launched its preloaded enVista Envy full range of vision intraocular lens in Europe, expanding its premium IOL portfolio alongside LuxLife for cataract and refractive surgeons. The diffractive lens, built on the established enVista platform, is designed to provide a continuous range of vision with strong tolerance to dysphotopsia, supported by clinical data from the U.S. and Canada showing high patient satisfaction and minimal visual disturbances.
The product is paired with the new EyeGility delivery system, which enables smooth, one-handed lens implantation through a 2 mm incision and offers extended standby time to streamline operating room workflows. By combining advanced optic design, finer astigmatism correction steps and a surgeon-friendly delivery system, the launch strengthens Bausch + Lomb’s competitive position in Europe’s premium cataract surgery market and may enhance outcomes for both surgeons and patients seeking fuller visual range.
The most recent analyst rating on (BLCO) stock is a Hold with a $16.34 price target. To see the full list of analyst forecasts on Bausch + Lomb Corporation stock, see the BLCO Stock Forecast page.
Spark’s Take on BLCO Stock
According to Spark, TipRanks’ AI Analyst, BLCO is a Neutral.
The score is most constrained by weak financial performance—multi-year net losses and negative free cash flow—despite solid revenue growth and a supportive balance sheet in the latest period. Offsetting this, the earnings call was strong with clear 2026 guidance for improved margins and EBITDA growth, and the technical setup is constructive with the stock trending above key moving averages. Valuation is held back by negative earnings and no stated dividend support.
To see Spark’s full report on BLCO stock, click here.
More about Bausch + Lomb Corporation
Bausch + Lomb is a global eye health company that develops and markets contact lenses, prescription ophthalmic drugs, over-the-counter eye care products and surgical devices. With a longstanding focus on innovation in vision care, the company targets patients, eye care professionals and surgical centers worldwide, aiming to improve outcomes across a broad range of eye conditions.
Average Trading Volume: 415,885
Technical Sentiment Signal: Buy
Current Market Cap: $5.79B
See more insights into BLCO stock on TipRanks’ Stock Analysis page.
